Clinical Trial
Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment forPD symptoms, levodopa. In this study, we will test if biochemical devices are equal to the clinical rating system in measuring dyskinesias.
Agency:
Department of Veterans Affairs
Phase:
N/A Study Design:
Case Control, Prospective
Condition:
Dyskinesias
Intervention type:
Drug
Intervention Name:
Levodopa (delivered intravenously)
Information Retrieved from Source:
Tuesday, 21 October 2008 Reference:
Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol. 1994;36(1):27-31.
Gordon AM, Ingvarsson PE, Forssberg H. Anticipatory control of manipulative forces in Parkinson's disease. Exp Neurol. 1997;145(2 Pt 1):477-88.
Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med. 1984;310(8):483-8.
Manson AJ, Brown P, O'Sullivan JD, Asselman P, Buckwell D, Lees AJ. An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatr. 2000;68(2):196-201.